• Citer

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis.

par Rothé, Françoise ;Venet, David ;Peeters, Dieter;Rouas, Ghizlane;Rediti, Mattia ;Smeets, Dominiek;Dupont, Floriane ;Campbell, Peter;Lambrechts, Diether;Dirix, Luc Y;Sotiriou, Christos ;Ignatiadis, Michail
Référence NPJ breast cancer, 8, 1, page (79)
Publication Publié, 2022-07-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Single cell technologies allow the interrogation of tumor heterogeneity, providing insights into tumor evolution and treatment resistance. To better understand whether circulating tumor cells (CTCs) could complement metastatic biopsies for tumor genomic profiling, we characterized 11 single CTCs and 10 pooled CTC samples at the mutational and copy number aberration (CNA) levels, and compared these results with matched synchronous tumor biopsies from 3 metastatic breast cancer patients with triple-negative (TNBC), HER2-positive and estrogen receptor-positive (ER+) tumors. Similar CNA profiles and the same patient-specific driver mutations were found in bulk tissue and CTCs for the HER2-positive and TNBC tumors, whereas different CNA profiles and driver mutations were identified for the ER+ tumor, which presented two distinct clones in CTCs defined by mutations in ESR1 Y537N and TP53, respectively. Furthermore, de novo mutational signatures derived from CTCs described patient-specific biological processes. These data suggest that tumor tissue and CTCs provide complementary clinically relevant information to map tumor heterogeneity and tumor evolution.